- Supported exchanges /
- AU /
- BOT.AU
Botanix Pharmaceuticals Ltd (BOT AU) stock market data APIs
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.
Botanix Pharmaceuticals Ltd Financial Data Overview
0.415 | |
0.425 | |
- | |
0.43 | |
0.41 | |
0.115-0.445 | |
762 M | |
1 814 M | |
2 069 K | |
1.713 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Botanix Pharmaceuticals Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 069 K
- EBITDA -13 980 337
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Botanix Pharmaceuticals Ltd Earnings via APIs
- Latest Release 2024-08-30
- EPS/Forecast NaN
Get Botanix Pharmaceuticals Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: